Structure-based discovery of nonhallucinogenic psychedelic analogs
The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Drugs that target the human serotonin 2A receptor (5-HT 2A R) are used to treat neuropsychiatric diseases; however, many have hallucinogenic effects, hampering their use. Here, we present structures of 5-HT 2A R complexed with the psychedelic drugs psilocin (the active metabolite of psilocybin) and d -lysergic acid diethylamide (LSD), as well as the endogenous neurotransmitter serotonin and the nonhallucinogenic psychedelic analog lisuride. Serotonin and psilocin display a second binding mode in addition to the canonical mode, which enabled the design of the psychedelic IHCH-7113 (a substructure of antipsychotic lumateperone) and several 5-HT 2A R β-arrestin–biased agonists that displayed antidepressant-like activity in mice but without hallucinogenic effects. The 5-HT 2A R complex structures presented herein and the resulting insights provide a solid foundation for the structure-based design of safe and effective nonhallucinogenic psychedelic analogs with therapeutic effects.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additionally, to target 5-HT 2A R, the combination of LSD and psilocybin can lead to biased activation of the mediated signaling pathway and produce antidepressant effects without the side effects of hallucinations. 387”
From Major depressive disorder: hypothesis, mechanism, prevention and treatment (2024) · cites this paper as [387]
In the citing paper
“While LSD binds to the orthosteric site of the 5-HT 2A R, certain ergoline-like analogs of LSD bind to the 5-HT 2A R at an extended binding pocket (Cao et al., 2022).”
From Psychedelics and Neural Plasticity: Therapeutic Implications (2022) · cites this paper as Cao et al., 2022
In the citing paper
“In a separate study, the psychedelic analog IHCH-7113 and several other 5-HT 2A R b -arrestin-biased agonists also demonstrate antidepressant-like activity in mice without hallucinogenic effects (Cao et al., 2022), although their dendritic and synaptic effects remain to be elucidated.”
From Psychedelics and Neural Plasticity: Therapeutic Implications (2022) · cites this paper as Cao et al., 2022
Citations
Cites
PHENIX : a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909052925 · Cited by 23,716
Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047337 · Cited by 16,463
Integration, scaling, space-group assignment and post-refinement
Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047374 · Cited by 2,528
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201
The expanded biology of serotonin
Berger, M., Gray, J. A., & Roth, B. L. (2009) · Annual Review of Medicine · doi:10.1146/annurev.med.60.042307.110802 · Cited by 2,100
Nichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Trial of Psilocybin versus Escitalopram for Depression
Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032994 · Cited by 1,391
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up
Carhart-Harris, R. L., Bolstridge, M., Day, C. M. J., Rucker, J., Watts, R., Erritzoe, D. E., Kaelen, M., Giribaldi, B., Bloomfield, M., Pilling, S., et al. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4771-x · Cited by 970
Operational models of pharmacological agonism
Black, J. W., & Leff, P. (1983) · Proceedings of the Royal Society of London. Series B. Biological Sciences · doi:10.1098/rspb.1983.0093 · Cited by 951
Research works printed but not linked: 3
- A. S. A. T. Shulgin PIHKAL: A Chemical Love Story (Transform Press 1991).
- A. S. A. T. Shulgin TIHKAL: The Continuation (Transform Press 1997).
- 10.1073/pnas.0708862105 · DOI · Paper page
Cited by
Items 101–200 of 314
Lucido, M. J., & Dunlop, B. W. (2025) · Brain Sciences · doi:10.3390/brainsci15020161 · Cited by 23
Biased GPCR Signaling: Possible Mechanisms and Therapeutic Applications
Fan, L., & Wang, S. (2025) · Biochemistry · doi:10.1021/acs.biochem.4c00827 · Cited by 21
Self-citationChristofidi, M., Tzortzini, E., Mavromoustakos, T., & Kolocouris, A. (2025) · Biochemistry · doi:10.1021/acs.biochem.5c00145 · Cited by 20
Arrate, I. M., Miranda-Azpiazu, P., Horrillo, I., Díez-Alarcia, R., & Meana, J. J. (2024) · British Journal of Pharmacology · doi:10.1111/bph.16368 · Cited by 22
Pathway-selective 5-HT1AR agonist as a rapid antidepressant strategy
Wang, C., Zhang, N., Shao, Y., Li, T., Zhang, M., Gao, M., Liang, Y., Wang, Y., Xue, T., Shi, Y., et al. (2025) · Cell · doi:10.1016/j.cell.2025.10.022 · Cited by 18
Liu, G., Ma, L., Qu, Y., Wan, X., Xu, D., Zhao, M., Murayama, R., & Hashimoto, K. (2023) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2023.173659 · Cited by 19
Concurrent stress modulates the acute and post-acute effects of psilocybin in a sex-dependent manner
Farinha‐Ferreira, M., Miranda‐Lourenço, C., Galipeau, C., Lenkei, Z., & Sebastião, A. M. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110280 · Cited by 20
Glatfelter, G. C., Chojnacki, M. R., McGriff, S. A., Wang, T., & Baumann, M. H. (2022) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00237 · Cited by 18
Deng, J., Zhang, H., Li, Y., Wei, K. X., Zhang, X., Yang, Y., & Zhang, J. (2022) · Chemical Engineering Journal · doi:10.1016/j.cej.2022.139993 · Cited by 18
Emergence of specific binding and catalysis from a designed generalist binding protein
Chen, Y., Bhattacharya, S., Bergmann, L., Correy, G. J., Tan, S. K., Hou, K., Biel, J. T., Lu, L., Bakanas, I. J., Gestwicki, J. E., et al. (2026) · Nature Chemistry · doi:10.1038/s41557-026-02125-6 · Cited by 20
Neurotransmitter recognition by human vesicular monoamine transporter 2
Im, D., Jormakka, M., Juge, N., Kishikawa, J.-I., Kato, T., Sugita, Y., Noda, T., Uemura, T., Shiimura, Y., Miyaji, T., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51960-z · Cited by 23
Zheng, Q., Liu, F., Xu, S., Hu, J., Lu, H., & Liu, T. (2023) · Journal of Safety Science and Resilience · doi:10.1016/j.jnlssr.2023.10.002 · Cited by 19
Synthetic surprise as the foundation of the psychedelic experience
Filippo, R. D., & Schmitz, D. (2024) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2024.105538 · Cited by 19
Arias, H. R., Rudin, D., Hines, D. J., Contreras, A., Gulsevin, A., Manetti, D., Anouar, Y., Deurwaerdère, P. D., Meiler, J., Romanelli, M. N., et al. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176329 · Cited by 18
Atiq, M. A., Baker, M. R., Voort, J. L. V., Vargas, M. V., & Choi, D. (2024) · Psychopharmacology · doi:10.1007/s00213-024-06599-5 · Cited by 18
Psychedelics and Consciousness: Expanding the Horizons of Mind and Therapy
Zhang, M., Wang, Y., Gao, T., & Wang, X. (2024) · Research · doi:10.34133/research.0495 · Cited by 17
Schmitz, G. P., Chiu, Y.-T., König, G. M., Kostenis, E., Roth, B. L., & Herman, M. A. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.11.15.516655 · Cited by 23
Jastrzębski, M. K., Wójcik, P., Grudzińska, A., Andreozzi, G., Vetrò, T., Asim, A., Mudgal, A., Czapiński, J., Wróbel, T. M., Bartuzi, D., et al. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.07.002 · Cited by 15
Agrawal, R. G., Gillie, D. J., Mungenast, A. E., Chytil, M., Engel, S. R., Wu, M. C., Rasmussen, K., Salinas, E. O., & Olson, D. E. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00667 · Cited by 18
Non-hallucinogenic Psychedelic Analog Design: A Promising Direction for Depression Treatment
Yin, Y., & Gao, T. (2022) · Neuroscience Bulletin · doi:10.1007/s12264-022-00933-7 · Cited by 16
Liu, X., Luo, M., Wang, Z., Yang, S. J., Su, M., Wang, Y., Wang, W., Sun, Z., Cai, Y., Wu, L., et al. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.155324 · Cited by 17
Self-citationSix-Step Synthesis of (±)-Lysergic Acid
Knight, B. J., Harbit, R. C., & Smith, J. M. (2023) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.2c02564 · Cited by 16
Neuropsychopharmacology of hallucinogenic and non‐hallucinogenic 5‐HT 2A receptor agonists
Sharp, T., & Ippolito, A. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70050 · Cited by 17
Chemistry/structural biology of psychedelic drugs and their receptor(s)
Gumpper, R. H., & Nichols, D. E. (2024) · British Journal of Pharmacology · doi:10.1111/bph.17361 · Cited by 14
Adebo, M., Bonnet, M., Laouej, O., Defaix, C., McGowan, J. C., Butlen‐Ducuing, F., David, D. J. P., Poupon, E., Tritschler, L., & Gardier, A. M. (2025) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.70038 · Cited by 14
Everaert, J., Leus, K., Rijckaert, H., Debruyne, M., Hecke, K. V., Morent, R., Geyter, N. D., Speybroeck, V. V., Voort, P. V. D., & Stevens, C. V. (2023) · Green Chemistry · doi:10.1039/d3gc00167a · Cited by 14
μ-opioid receptor agonists and psychedelics: pharmacological opportunities and challenges
Salinsky, L. M., Merritt, C. R., Zamora, J. C., Giacomini, J. L., Anastasio, N. C., & Cunningham, K. A. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1239159 · Cited by 16
Exploring structure-based drug discovery of GPCRs beyond the orthosteric binding site
Chen, Z., Ren, X., Zhou, Y., & Huang, N. (2024) · hLife · doi:10.1016/j.hlife.2024.01.002 · Cited by 15
Self-citationG protein-coupled receptors as targets for transformative neuropsychiatric therapeutics
Schmitz, G. P., & Roth, B. L. (2023) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00397.2022 · Cited by 13
Molecular insights into GPCR mechanisms for drugs of abuse
Sánchez-Reyes, O. B., Zilberg, G., McCorvy, J. D., & Wacker, D. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.105176 · Cited by 13
Evaluating the potential for psilocybin as a treatment for post-traumatic stress disorder
Miller, C., & Zoladz, P. R. (2024) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.124.002237 · Cited by 13
Meccia, J., Lopez, J., & Bagot, R. C. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06297-0 · Cited by 14
Pagire, H. S., Pagire, S. H., Jeong, B.-K., Choi, W., Oh, C. J., Lim, C. W., Kim, M., Yoon, J., Kim, S. S., Bae, M. A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-44874-3 · Cited by 15
MouseGPT: A Large-scale Vision-Language Model for Mouse Behavior AnalysisPreprint
Xu, T. G., Zhou, T., Wang, Y., Yang, P., Tang, S., Shao, K., Tang, Z., Liu, Y., Chen, X., Liu, Y., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.27.645630 · Cited by 18
Structural basis of psychedelic LSD recognition at dopamine D1 receptor
Fan, L., Zhuang, Y., Wu, H., Li, H., Xu, Y., Wang, Y., He, L., Wang, S., Chen, Z., Cheng, J., et al. (2024) · Neuron · doi:10.1016/j.neuron.2024.07.003 · Cited by 13
Self-citationClassical psychedelics’ action on brain monoaminergic systems
Butler, J. J., Ricci, D., Aman, C., Beyeler, A., & Deurwaerdère, P. D. (2024) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2024.106669 · Cited by 12
Preclinical models for evaluating psychedelics in the treatment of major depressive disorder
Alexander, L., Anderson, D., Baxter, L., Claydon, M. D. B., Rucker, J., & Robinson, E. S. J. (2024) · British Journal of Pharmacology · doi:10.1111/bph.17370 · Cited by 13
Ubhayarathna, M., Langmead, C. J., Diepenhorst, N. A., & Stewart, G. D. (2023) · British Journal of Pharmacology · doi:10.1111/bph.16233 · Cited by 13
The possible place for psychedelics in pharmacotherapy of mental disorders
Wojtas, A. (2023) · Pharmacological Reports · doi:10.1007/s43440-023-00550-9 · Cited by 14
The therapeutic potential of psychedelics
Schindler, E. A. D., & D’Souza, D. C. (2022) · Science · doi:10.1126/science.abn5486 · Cited by 13
Islam, M. T., Chowdhury, R., Bhuia, M. S., Chakrabarty, B., Kundu, N., Akbor, M. S., Sheikh, S., Chowdhury, R. I., Ansari, S. A., Ansari, I. A., et al. (2024) · Drug Development Research · doi:10.1002/ddr.22259 · Cited by 11
Billard, É., Torbey, A. G., Inserra, A., Grant, E., Bertazzo, A., Gregorio, D. D., Comai, S., Chatenet, D., Gobbi, G., & Hébert, T. E. (2025) · Cellular Signalling · doi:10.1016/j.cellsig.2025.111588 · Cited by 11
Proton perception and activation of a proton-sensing GPCR
Chen, L.-N., Zhou, H., Xi, K., Cheng, S., Liu, Y., Fu, Y., Ma, X., Xu, P., Ji, S., Wang, W., et al. (2025) · Molecular Cell · doi:10.1016/j.molcel.2025.02.030 · Cited by 11
Are we hallucinating or can psychedelic drugs modulate the immune system to control inflammation?
Qureshi, O., Cowley, J., Pegg, A., Cooper, A. J., Gordon, J., Brady, C., Belli, A., Butterworth, S., Upthegrove, R., Andrews, N., et al. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70138 · Cited by 13
Therapeutic potential of psychedelics: History, advancements, and unexplored frontiers
Maia, J. M., de Oliveira, B. S. A., Branco, L. G. S., & Soriano, R. N. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2024.110951 · Cited by 12
Yao, H., Wang, X., Chi, J., Chen, H., Liu, Y., Jiayi, Y., Yu, J., Ruan, Y., Xiang, X., Pi, J., et al. (2024) · Molecules · doi:10.3390/molecules29050964 · Cited by 12
Self-citationKalsoom, I., Shehzadi, K., Li, H., Wen, H., & Yu, M. (2024) · Topics in Current Chemistry · doi:10.1007/s41061-024-00465-w · Cited by 12
Zhang, M., Yang, Y., Yang, Z., Wen, X., Zhang, C., Xiao, P., Wang, Y., Sun, J., Wang, H., & Wang, X. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.117049 · Cited by 12
Cui, M., Lu, Y., Mezei, M., & Logothetis, D. E. (2024) · Molecules · doi:10.3390/molecules29204935 · Cited by 10
The therapeutic potential of psilocybin beyond psychedelia through shared mechanisms with ketamine
Park, D., Lee, G., Lee, W.-G., Kim, B. S., Lee, Y., & Kim, J. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03100-2 · Cited by 14
Fryc, M., Kluzik, D., Czopek, A., Jończyk, J., & Zagórska, A. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110622 · Cited by 10
The ABCs of psychedelics: a preclinical roadmap for drug discovery
Kwan, A. C., Mantsch, J. R., & McCorvy, J. D. (2025) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2025.07.017 · Cited by 11
Palhas, M. L. C., Corne, R., & Mongeau, R. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111533 · Cited by 12
CCNP Innovations in Neuropsychopharmacology Award
Gobbi, G. (2024) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.240037 · Cited by 11
Lin, C., Lin, H.-Y., Peng, W., & Wu, L. Y. (2024) · Current Medicinal Chemistry · doi:10.2174/0109298673299665240924090617 · Cited by 11
Viohl, N., Zanjani, A. A. H., & Khandelia, H. (2025) · FEBS Letters · doi:10.1002/1873-3468.15099 · Cited by 10
Gonçalves, K. T. D. C., Tavares, V. D. D. O., Barros, M. L. D. M., de Brito, A. J. C., Cavalcanti-Ribeiro, P., Palhano-Fontes, F., Falchi-Carvalho, M., Arcoverde, E., SANTOS, R. G. D., Hallak, J. E. C., et al. (2024) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-024-01925-6 · Cited by 13
Biased Signaling in Psychedelic Action
Wacker, D., & McCorvy, J. D. (2025) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-062124-012545 · Cited by 10
Drewko, A. J., Habets, R. L. P., & Brunt, T. M. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03169-9 · Cited by 17
New Piperazine Derivatives of 6-Acetyl-7-hydroxy-4-methylcoumarin as 5-HT1A Receptor Agents
Ostrowska, K., Leśniak, A., Gryczka, W., Dobrzycki, L. M., Bujalska‐Zadrożny, M., & Trzaskowski, B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032779 · Cited by 9
Neurobiology of the Antidepressant Effects of Serotonergic Psychedelics: A Narrative Review
Chisamore, N., Kaczmarek, E. S., Le, G. H., Wong, S., Orsini, D. K., Mansur, R. B., McIntyre, R. S., & Rosenblat, J. D. (2024) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-024-00319-8 · Cited by 9
MacGowan, S. A., Madeira, F., Britto-Borges, T., & Barton, G. J. (2024) · Communications Biology · doi:10.1038/s42003-024-06117-5 · Cited by 8
Vollebregt, R., Storm, A. E. M., Lucassen, P. J., & Somers, M. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106529 · Cited by 11
Zhu, H., Liu, X., Wang, X., Li, Y., Ma, F., Tan, B., Zhou, P., Fu, F., & Su, R. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176038 · Cited by 8
Self-citationFouillen, A., Couvineau, P., Gaibelet, G., Riché, S., Orcel, H., Mendre, C., Kanso, A., Lanotte, R., Nguyen, J., Dimon, J., et al. (2024) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2024.10.039 · Cited by 9
Zalsupindole: A Non-Hallucinogenic Psychoplastogen Advancing Psychedelic-Inspired Therapeutics
Salfiti, M., Kyriazis, M., & Mikellides, G. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00707 · Cited by 9
Matsoukas, M., Ciruela-Jardí, M., Gallo, M., Ferré, S., Andreu, D., Casadó, V., Pardo, L., & Moreno, E. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01796 · Cited by 7
Biological studies of clavine alkaloids targeting CNS receptors
Tasker, N. R., Pazur, E. J., & Wipf, P. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1286941 · Cited by 7
Chen, A., Su, C., Zhang, Z., & Zhang, H. (2025) · Pharmaceuticals · doi:10.3390/ph18030292 · Cited by 7
Targeting the 5-HT2A Receptor for Developing Psychedelic Drugs and Beyond
Ali, S., Tian, X., Cunningham, K. A., & Zhou, J. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01156 · Cited by 9
Sink, A., Pottie, E., Carter, S. J., Tombari, R. J., Weber, V., Carloni, P., Rossetti, G., Olson, D. E., Stove, C. P., & Decker, M. W. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00442 · Cited by 6
de Araújo, J. I. F., do Nascimento, G. A., Vieira‐Neto, A. E., Magalhães, F. E. A., & Campos, A. R. (2025) · Behavioural Brain Research · doi:10.1016/j.bbr.2025.115415 · Cited by 6
Kehler, J., & Lindskov, M. S. T. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251330741 · Cited by 9
Membrane Permeation of Psychedelic Tryptamines by Dynamic Simulations
Palmisano, V. F., Agnorelli, C., Fagiolini, A. M., Erritzøe, D., Nutt, D. J., Faraji, S., & Nogueira, J. J. (2024) · Biochemistry · doi:10.1021/acs.biochem.3c00598 · Cited by 10
Synthesis and bioactivity of psilocybin analogues containing a stable carbon–phosphorus bond
Vandevelde, M., Simoens, A., Vandekerckhove, B., & Stevens, C. V. (2024) · RSC Medicinal Chemistry · doi:10.1039/d4md00043a · Cited by 6
Identification of Psychoplastogenic Tropanes Lacking Muscarinic Activity
Warren, H. T., Chow, W. L., Chytil, M., Rasmussen, K., & Olson, D. E. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01204 · Cited by 6
Syed, O. A., Petranker, R., & Tsang, B. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106204 · Cited by 7
Tomašević, N., Vujović, M., Kostić, E., Ragavendran, V., ARSIC, B. B., Matić, S. L., Božović, M., Fioravanti, R., Proia, E., Ragno, R., et al. (2023) · Molecules · doi:10.3390/molecules28176236 · Cited by 6
The molecular basis of the antidepressant action of the magic mushroom extract, psilocin
Zanjani, A. A. H., Nguyen, T. Q. T., Jacobsen, L., & Khandelia, H. (2023) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2023.140914 · Cited by 7
What are set and setting: Reducing vagueness to improve research and clinical practice
Patch, K., & Smith, W. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251337372 · Cited by 8
Better Biomarkers, Faster Drugs, Stronger Models: Progress Towards Precision Psychiatry.
Siegel, J. S., Pearson, C. S., & Lenze, E. J. (2023) · PubMed Central · Cited by 6
Psychedelics for treating psychiatric disorders: from circuit mechanisms to applications
Li, J., Jiang, Y., Cheng, D., Cheng, J., Ji, H., Wang, X., & Yuan, T. (2024) · 中国科学通报:英文版 · doi:10.1016/j.scib.2024.11.033 · Cited by 5
Self-citationStructural insights into ligand recognition and G protein preferences across histamine receptors
Matsuzaki, Y., Sano, F. K., Oshima, H. S., Akasaka, H., Kobayashi, K., Tanaka, T., Itoh, Y., Shihoya, W., Kise, Y., Kusakizako, T., et al. (2025) · Communications Biology · doi:10.1038/s42003-025-08363-7 · Cited by 5
Biased agonism in psychopharmacology: an opportunity to improve efficacy and safety of treatments
Le, G. H., Wong, S., Bargiota, S. I., Swainson, J., Lo, H. K. Y., Orsini, D. K., Teopiz, K. M., Guillen-Burgos, H. F., Lim, P. K., & McIntyre, R. S. (2025) · CNS Spectrums · doi:10.1017/s109285292510045x · Cited by 6
Highly efficient synthesis of lysergic acid using engineered budding yeast
Wu, N., Yao, M., Xiao, W., Wang, Y., & Yuan, Y. (2024) · Green Chemistry · doi:10.1039/d4gc03756a · Cited by 5
Development of the novel amylin and calcitonin receptor activators by peptide mutagenesis
Lee, S. M. (2024) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2024.110191 · Cited by 5
Jiang, S., Ge, D., Song, B., Deng, X., Liu, Z., He, J., Sun, J., Zhu, Z. H., Meng, Z., & Zhu, Y. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110264 · Cited by 5
Psychedelics in Psychiatry: Oh, What A Trip!
Fonzo, G. A., Nemeroff, C. B., & Kalin, N. H. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20241025 · Cited by 5
Kim, S., Yang, S., Jung, J., Choi, J., Kang, M., & Joo, J. (2025) · Advanced Science · doi:10.1002/advs.202413786 · Cited by 10
Elisi, G. M., & Bottegoni, G. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108905 · Cited by 5
Introduction to the chemistry and pharmacology of psychedelic drugs
Walker, S. R., Pullella, G. A., Piggott, M., & Duggan, P. J. (2023) · Australian Journal of Chemistry · doi:10.1071/ch23050 · Cited by 6
da Cruz, L. V. M., Bienemann, B., Palhano-Fontes, F., Tófoli, L. F., de Araújo, D. B., & Mograbi, D. C. (2023) · Scientific Reports · doi:10.1038/s41598-023-44193-5 · Cited by 13
How Ligands Achieve Biased Signaling toward Arrestins
Jiang, Q., & Che, T. (2025) · Biochemistry · doi:10.1021/acs.biochem.4c00843 · Cited by 4
Puigseslloses, P., Nadal‐Gratacós, N., Fumàs, B., Modenutti, C. P., Pottie, E., Ortigosa, J., Pablo-Quesada, A., Riera-Colomer, C., Ettcheto, M., Berzosa, X., et al. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03308-2 · Cited by 6
Regni, A., Bartoccini, F., & Piersanti, G. (2025) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.5c02229 · Cited by 4
Pyka, P., Garbo, S., Murzyn, A., Satała, G., Janusz, A., Górka, M., Pietruś, W., Mituła, F., Popiel, D., Wieczorek, M., et al. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107668 · Cited by 6
The immunomodulatory effects of psychedelics in Alzheimer’s disease-related dementia
Hosseini, A. M., Khaleghzadeh‐Ahangar, H., & Rahimi, A. (2024) · Neuroscience · doi:10.1016/j.neuroscience.2024.11.062 · Cited by 4
Exploring a Druggable Hydrophobic Tunnel in the 5-HT2A Receptor with Potent Phenethylamines
Simon, Í. A., Pottie, E., Jensen, M. K., Harpsøe, K., Jensen, A. A., Kristensen, J. L., Stove, C. P., & Poulie, C. B. M. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c01973 · Cited by 4
Soares, B. A., Yempala, T., Martínez-Afani, D., Acevedo-Fuentes, W., Brea, J. M., Loza, M. I., Cimadevila, M., & Cassels, B. K. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00639 · Cited by 4
Ye, J., Li, P., Liu, P., Pei, W., Wang, R., Liu, H., Ma, C., & Zhao, D. (2024) · International Journal of COPD · doi:10.2147/copd.s471817 · Cited by 5
Metadata
- Authors
- Cao, D., Yu, J., Wang, H., Luo, Z., Liu, X., He, L., Qi, J., Fan, L., Tang, L., Chen, Z., Li, J., Cheng, J., & Wang, S.
- Affiliations
- Chinese Academy of Sciences (CN)
- ShanghaiTech University (CN)
- Soochow University (CN)
- Corresponding author
- Cao, Dongmei
- Yu, Jing
- Wang, Huan
- Luo, Zhipu
- Liu, Xinyu
- Cheng, Jianjun
- Wang, Sheng
- ORCID
- Venue
- Science
- Published
- 2022-01-28
- Volume
- 375
- Issue
- 6579
- Pages
- 403-411
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W4210474529
- Cited by
- 312
- References
- 46
- Citations by year
- 2026: 50 · 2025: 77 · 2024: 84 · 2023: 69 · 2022: 32
- FWCI
- 59.96
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- 5-HT2A receptor, psilocin, LSD, lisuride, structure-based drug design, receptor-ligand complex, lumateperone, antidepressant-like effects, hallucinogenic effects
- MeSH terms
- Animals, Antidepressive Agents, Binding Sites, Hallucinations, Hallucinogens, Heterocyclic Compounds, 4 or More Rings, Humans, Ligands, Lisuride, Lysergic Acid Diethylamide, Protein Conformation, Psilocybin, Serotonin, Structure-Activity Relationship, Drug Design, Signal Transduction, Crystallography, X-Ray, Arrestin, Receptor, Serotonin, 5-HT2A, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.